

Supplementary Figure 1: Schematic diagram of the relationships among co-mutations, tumor immune microenvironment, and immunotherapy. *ALK*: ALK receptor tyrosine kinase; *CDKN2A/B*: Cyclin-dependent kinase inhibitor 2A/B; *EGFR*: Epidermal growth factor receptor; *KEAP1*: Kelch-Like ECH-associated protein 1; *KRAS*: Kirsten rat sarcoma viral oncogene homolog; MAPK: Mitogen-activated protein kinase; PD-1: Programmed cell death 1; PD-L1: Programmed death ligand-1; STING: Stimulator of interferon genes; *STK11/LKB1*: Serine/threonine kinase 11/liver kinase B1; TMB: Tumor mutational burden; *TP53*: Tumor protein p53.